Incyclix Bio
Last verified 2026-05-22. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $50.0Mattributed |
|---|---|
| Latest round | series-b, $30.0M, 2025-10-01attributed |
| Founded | 2022 |
| Headquarters | Durham |
| Industry | healthcare |
| Stage | series-b+ |
| Website | incyclixbio.com |
Incyclix Bio develops cancer therapies that target the cell-cycle machinery, led by INX-315, a selective CDK2 inhibitor in clinical trials. It is aimed at patients with cancers driven by abnormal proliferation, including CDK4/6-resistant breast cancer and CCNE1-amplified tumors. It draws on its founders' long history in CDK inhibitor development.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-b | $30.0M | undisclosed |
Detected tech stack
Nginx, WordPress, Typekit, Adobe Fonts, Yoast SEO 27.1.1, Google Analytics, Google Tag Manager, Slick, jQuery Migrate 3.4.1, DoubleClick Floodlight, Contact Form 7 6.1.5, WP Engine
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $30.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $50.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | incyclixbio.com, read 2026-05-22 |
| Description | self-reported | incyclixbio.com, read 2026-05-22 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.